RXRX Recursion Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Recursion Pharmaceuticals is trading 12.5% down today after $200 million discounted share offering
Recursion Pharmaceuticals is trading at $3.64, down 12.50%, as its discounted share offering raises dilution concerns. - The $200 million offering comprises...
🔴 Recursion Pharmaceuticals is trading 6.7% down today after pricing $200 million offering below prior close
Recursion Pharmaceuticals is trading at $3.88, down 6.73%, as reports linked the decline to its discounted share offering. - The company priced a $200 million...
Recursion Pharmaceuticals prices $200M offering and reports clinical progress in third quarter 2026
Recursion Pharmaceuticals announced a preliminary third quarter 2026 cash balance of approximately $561 million and the pricing of a $200 million underwritten...
Recursion's Triple-Barrel Announcement Lifts Shares 10% — But Can Clinical Promise Outrun Dilution?
Shares of Recursion Pharmaceuticals surged +10.4% to $4.13 as the AI-driven biotech orchestrated a carefully timed trifecta: updated trial data for two key...
🟢 Recursion Pharmaceuticals is trading 10.43% up today after REC-4881's 47% median polyp-burden reduction
Recursion Pharmaceuticals is trading at $4.13, up 10.43% in live trading, amid October 15 clinical updates. - REC-4881 updates included a 47% median reduction...
🟢 Recursion Pharmaceuticals is trading 5.48% up today amid trial updates and Sanofi's $10 million milestone
Recursion Pharmaceuticals is trading at $3.94, up 5.48%, amid October 15 clinical updates and a Sanofi milestone announcement. - Recursion reported...
🟢 Recursion Pharmaceuticals is trading 5.75% up today with no clear catalyst identified
Recursion Pharmaceuticals is trading 5.75% up at $3.92, with no single cause established for the gain. - On October 15, the company announced positive clinical...
🔴 Recursion Pharmaceuticals is trading 6.2% down in pre-market on October 15, 2026, on rate concerns
Recursion Pharmaceuticals is trading 6.15% down in pre-market at $3.51 on October 15, 2026, as broader market pressure weighs on growth shares. - September...
🔴 Recursion Pharmaceuticals is trading 4.04% down today as inflation and rate-hike bets pressured growth shares
Recursion Pharmaceuticals is trading at $3.68, down -4.04%, as hotter-than-expected September inflation and rising rate-hike bets pressured growth-sensitive...
🔴 Recursion Pharmaceuticals is trading 4.2% down on October 13, 2026 amid biotech sector weakness
Recursion Pharmaceuticals is trading at $3.84, down 4.19% on October 13, 2026, with no clear company-specific catalyst identified; biotech sector weakness may...
🔴 Recursion Pharmaceuticals is trading 4.7% down
Recursion Pharmaceuticals is trading at $4.16, down 4.70%, with no clear company-specific explanation identified for the October 12 decline. - A pre-market...
🟢 Recursion Pharmaceuticals is trading 5.5% up in pre-market on October 12, 2026
Recursion Pharmaceuticals is trading at $4.60, up 5.50% in pre-market on October 12, with no clear company-specific catalyst identified. - The latest...
🟢 Recursion Pharmaceuticals is trading 11% up today amid a 2.50% XBI gain
Recursion Pharmaceuticals is trading 10.51% higher at $4.37, alongside biotech-sector strength; the XBI is up 2.50%. - Positive sentiment also surrounds...
🟢 Recursion Pharmaceuticals is trading 5% up today amid biotech-sector strength
Recursion Pharmaceuticals is trading at $4.16, up 5.32%, in live trading on October 9, 2026, with broader biotech strength offering the clearest context for...
🔴 Recursion Pharmaceuticals is trading 10.2% down today amid biotech-sector weakness
Recursion Pharmaceuticals is trading 10.24% down at $3.83 amid biotech-sector weakness, with no clear company-specific catalyst identified for the October 8,...
🔴 Recursion Pharmaceuticals is trading 5% down today as catalyst remains unclear
Recursion Pharmaceuticals is trading 4.80% down at $4.07 on October 8, 2026, with no clear company-specific announcement identified to explain the decline. -...
🔴 Recursion Pharmaceuticals is trading 4.75% down today amid biotech-sector weakness
Recursion Pharmaceuticals is trading at $4.38, with a -4.75% change, amid likely biotech-sector weakness; no clear company-specific announcement explains the...
🔴 Recursion Pharmaceuticals is trading at 4.7% down today alongside biotech ETF XBI's 2.50% decline
Recursion Pharmaceuticals is trading 4.7% lower at $4.55, with biotech-sector weakness a possible backdrop. - Biotech ETF XBI is down 2.50%; no clear...
Recursion's Tempus Deal Shrinks Its Cash Outflows and Licenses Its AI — But Can a $12 Million Side Deal Justify a 26% Weekly Rally?
Shares of Recursion Pharmaceuticals surged +6.3% to $5.08 on October 6, extending a blistering weekly run from $4.03 to over five dollars — a roughly 26% gain...
🟢 Recursion Pharmaceuticals jumps 6.3% with Cathie Wood's ARK Invest loading up shares, building on Tempus AI partnership optimism
Recursion Pharmaceuticals is trading at $5.08, up +6.28%, driven by fresh investment from Cathie Wood's ARK Invest and sustained optimism surrounding its...